What is the 13F Pro Quality Score for PASG?

13F Pro ranks Passage BIO, Inc. (PASG) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View PASG's current score at https://13fpro.ai/research/PASG (free sign-up required for the full ranking).

Where does 13F Pro source PASG data?

All Passage BIO, Inc. fundamentals and ownership data come directly from SEC EDGAR. Passage BIO, Inc. files with the SEC under CIK 1787297. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is PASG in?

Passage BIO, Inc. (PASG) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is PASG research updated on 13F Pro?

PASG's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Passage BIO, Inc.(PASG)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1787297 PASG stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Limited institutional coverage

Quality rankings require at least 50 unique 13-F institutional holders to ensure peer comparisons are meaningful. Only 34 institutional filers currently hold this stock.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

PASG Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Passage BIO, Inc. (PASG), a Healthcare sector company. PASG is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least 50 unique 13-f institutional holders to ensure peer comparisons are meaningful. only 34 institutional filers currently hold this stock. Based on the latest XBRL financial filings (Q1 2026), Passage BIO, Inc. reports net income of $-7.6M, free cash flow of $-13.0M. Top institutional holders of PASG by reported 13-F value include Lynx1 Capital Management, Vestal Point Capital,, RENAISSANCE TECHNOLOGIES, based on the most recent SEC filings. PASG trades on the Nasdaq exchange and files with the SEC under CIK 1787297. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate PASG daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Passage BIO, Inc. directly from SEC EDGAR.

Net Income

Q1 2026

$-7.6M

Free Cash Flow

Q1 2026

$-13.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Net Income

+29.2% YoY

$-46.0MFY 2025

FY22 $-136.1MFY23 $-102.1MFY24 $-65.0MFY25 $-46.0M

Operating Income

+30.0% YoY

$-49.3MFY 2025

FY22 $-138.4MFY23 $-108.4MFY24 $-70.4MFY25 $-49.3M

EPS (Diluted)

+31.8% YoY

$-14.35FY 2025

FY22 $-2.50FY23 $-1.86FY24 $-21.04FY25 $-14.35

Total Assets

-39.2% YoY

$62.3MFY 2025

FY22 $243.5MFY23 $150.5MFY24 $102.4MFY25 $62.3M

Op. Cash Flow

+34.3% YoY

$-31.5MFY 2025

FY22 $-118.2MFY23 $-78.3MFY24 $-48.0MFY25 $-31.5M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2019
Net Income	$-46.0M +29.2%	$-65.0M +36.3%	$-102.1M +25.0%	$-136.1M +26.6%	$-185.4M -306.2%	$-45.6M
Operating Income	$-49.3M +30.0%	$-70.4M +35.0%	$-108.4M +21.7%	$-138.4M +25.5%	$-185.7M -399.4%	$-37.2M
EPS (Diluted)	$-14.35 +31.8%	$-21.04 -1031.2%	$-1.86 +25.6%	$-2.50 +28.2%	$-3.48	—
Total Assets	$62.3M -39.2%	$102.4M -32.0%	$150.5M -38.2%	$243.5M -31.4%	$355.1M +98.8%	$178.6M
Operating Cash Flow	$-31.5M +34.3%	$-48.0M +38.7%	$-78.3M +33.8%	$-118.2M +6.8%	$-126.9M -218.0%	$-39.9M

AI Insight: PASG Financial Trends

Passage BIO is burning cash at a decelerating rate, but equity has eroded 87% since mid-2024—runway is critically constrained.

• Net losses narrowed from $19M (Q3 2024) to $8M (Q3 2025 and Q1 2026), showing operational discipline amid pre-revenue stage.

• Shareholder equity collapsed from $91M (Q2 2024) to $12M (Q1 2026)—company consuming ~$10M equity per quarter on average.

• Operating cash burn improved from $14M (Q1 2025) to $5M–$6M range (Q3 2025), but spiked to $13M outflow in Q1 2026.

⚠ Equity cushion of $12M at Q1 2026 implies <2 quarters of runway at current burn—financing or clinical milestone urgently needed.

⚠ Operating cash flow deteriorated sharply in Q1 2026 ($13M outflow) after improving trend—investigate timing or working capital shifts.

AI Insight: PASG Ratio Trends

Passage BIO remains deeply unprofitable with ROA deteriorating to -82.9% in Q1 2026, showing no meaningful progress toward profitability.

• ROA worsened from -41.8% in Q3 2025 to -82.9% in Q1 2026, a significant reversal after six quarters of gradual improvement.

• ROE remained severely negative across all periods, ranging from -70.6% to -131.9%, reflecting persistent net losses.

⚠ Q1 2026 ROA spike to -82.9% marks the worst quarter since Q1 2025's -71.7%, halting prior stabilization trend.

⚠ Lack of operating and net profit margin data limits visibility into expense management and path to breakeven.

Get alerted when PASG's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Passage BIO, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of PASG

Lynx1 Capital Management LP
$4.9M623,704 sh
Vestal Point Capital, LP
$2.4M305,000 sh
RENAISSANCE TECHNOLOGIES LLC
$1.0M133,612 sh
Eversept Partners, LP
$1.0M131,581 sh
VANGUARD CAPITAL MANAGEMENT LLC
$894.6K113,964 sh
Yiheng Capital Management, L.P.
$675.9K86,097 sh
Ikarian Capital, LLC
$534.8K68,124 sh
Erste Asset Management GmbH
$526.9K85,262 sh
GEODE CAPITAL MANAGEMENT, LLC
$324.9K41,380 sh
BlackRock, Inc.
$224.5K28,595 sh

Fund	Value	Shares
Lynx1 Capital Management LP	$4.9M	623,704
Vestal Point Capital, LP	$2.4M	305,000
RENAISSANCE TECHNOLOGIES LLC	$1.0M	133,612
Eversept Partners, LP	$1.0M	131,581
VANGUARD CAPITAL MANAGEMENT LLC	$894.6K	113,964
Yiheng Capital Management, L.P.	$675.9K	86,097
Ikarian Capital, LLC	$534.8K	68,124
Erste Asset Management GmbH	$526.9K	85,262
GEODE CAPITAL MANAGEMENT, LLC	$324.9K	41,380
BlackRock, Inc.	$224.5K	28,595

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put PASG on your watchlist

Track score changes the day Passage BIO, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is PASG a good stock to buy?

13F Pro's AI-powered analysis of Passage BIO, Inc. (PASG) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for PASG are available on the PASG stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own PASG?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling PASG. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Passage BIO, Inc.'s investment landscape.